rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GNBT !!!

2.656 Posts
Pagina: «« 1 ... 92 93 94 95 96 ... 133 »» | Laatste | Omlaag ↓
  2. [verwijderd] 9 maart 2006 22:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Vandaag was de stofzuiger wat minder dominant aanwezig dan gisteren. Vijf minuten vóór sluiting werd in een paar vegen de gehele laat van 2.14 tot 2.19 leeg gekocht. Vakkundig werd telkens de koers een paar punten terug gezet alsof er niets aan de hand was. Moet teamwork zijn.
  3. [verwijderd] 10 maart 2006 12:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    www.cbsnews.com/stories/2006/03/10/ap...

    De angst neemt toe...

    Vandaag moet miens inziens een bericht komen over dat griep vaccin.
    De aanvraag is op 10 feb. ingediend,binnen 30 dagen moet daaar reactie op komen.
    Zondag is het 12 maart dus voor zondag bericht.

    Men is, dat blijkt uit dit stukje van CBS al verschillende worst case senario's aan het uitdenken.
    De mens maakt zich zelf helemaal ziek van angst.

    Ben benieuwd vandaag,zeer goed voorgevoel.

    Groet,Ronald.
  5. [verwijderd] 11 maart 2006 11:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Aan de hoge omzetten en trend te zien was de $2,00 een mooie bodem.Zonder nieuws rustig omhoog naar $2,50 en met goed nieuws gaan we de komende weken knallen!!

    Gaat helemaal goed.

    Mcrel
  6. [verwijderd] 11 maart 2006 17:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zondag zijn de 30 dagen voorbij ddie de FDA heeft om te reageren op een indiening.
    ALs men maandag komt met goed nieuws kunnen we een eind omhoog.

    Groet, Ronald
  7. [verwijderd] 11 maart 2006 20:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Avian-Flu Concerns Overseas
    Damp U.S. Chicken Exports

    By SCOTT KILMAN and JANE ZHANG
    March 11, 2006; Page A5

    The Agriculture Department said the growing avian-influenza panic overseas is reducing U.S. chicken exports and warned that the deadly bird disease is getting closer to U.S. shores.

    "I can't build a cage around the United States," said Agriculture Secretary Mike Johanns. "For us, this is a situation where it is not about debating whether it will arrive, it's preparing for when it does arrive."

    The Asian strain of H5N1 bird flu, which can be spread by wild birds to poultry, is already causing big problems for U.S. chicken companies by damping foreign demand. Many consumers in countries where the virus has recently appeared in birds, such as France, Italy and Greece, are avoiding chicken, even though proper cooking kills the virus.

    PREVENTING A PANDEMIC

    • See an FAQ on avian flu, an interactive global map and track the latest developments in the Avian Flu News Tracker.

    • Plus, see complete coverage.

    According to the World Health Organization, the H5N1 virus has killed 97 people since 2003 in the developing world, where people routinely live in much closer contact with poultry than they do in the West.

    The USDA said Friday in its monthly update on world market conditions that it expects the U.S. chicken industry to export 5.3 billion pounds of meat this year, down 5.3% from its projection in December.

    The U.S. chicken industry relies on foreign customers to buy about one-third of its production of legs and thighs. The wholesale price of so-called dark meat has plunged to about 14 cents a pound in recent weeks, compared with about 42 cents a pound last summer.

    The export slowdown is forcing chicken-industry executives to consider reducing production, something historically they have been very slow to do when faced with market troubles. The U.S. industry's biggest exporting rival, Brazil, is already making plans to cut chicken production by roughly 15%, but USDA economists continue to see U.S. production climbing this year, up 2.3%.

    "It needs to get really bad before they start to act," said Adriaan Weststrate, head of the poultry-lending sector in North America for Dutch banking giant Rabobank Group.

    Many scientists believe that the deadly H5N1 strain, which originated in Asia, will most likely reach the U.S. through Asian birds that migrate in the spring to Alaska, where they can come in contact with North American birds that also come there to hatch their young before returning south. The first wave of Asian birds could arrive within several weeks, which has Bush administration officials sounding the alarm.

  9. [verwijderd] 14 maart 2006 09:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Word kunstmatig naar beneden geshuffeld door daytraders.
    Ik maak me geen zorgen,vogelgriep gekte word steeds erger.

    Kijk op het yahoo forum daar zitten veel meer mensen op .
    Groet,ROnald.
  10. [verwijderd] 14 maart 2006 14:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Source: Generex Biotechnology

    Generex Biotechnology to Present Its Avian Influenza Vaccine Program at DNA Forum in London
    Tuesday March 14, 8:30 am ET

    TORONTO--(MARKET WIRE)--Mar 14, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Dr. Douglas Powell, Ph.D., Director of Immunobiology at Antigen Express, Inc., the Company's wholly owned immunotherapeutics subsidiary, will present the Antigen Express H5N1 avian influenza vaccine program at the upcoming Third Annual DNA Vaccines Forum to be held in London, UK, March 17 - 18, 2006.
    ADVERTISEMENT


    The strategy employed by Antigen Express focusing on the development of its novel H5N1 avian influenza vaccine utilizes small portions of the H5 protein that are modified to enhance antigen-specific stimulation of T-helper cells. Upon infection, such T-helper cell responses enhance the speed and strength of neutralizing antibody production. It is anticipated that the vaccine being developed will both impart some level of protection on its own and enhance the activity of other types of avian influenza vaccines, including DNA vaccines.

    The meeting will focus on the latest advances involving DNA vaccine technology as well as clinical experiences and regulatory issues. All vaccines that are currently approved for human use are inactivated or attenuated (weakened) viruses or recombinant protein vaccines. DNA vaccines are a promising new approach with the potential to prevent many infectious diseases such as H5N1 influenza, anthrax and plague. Although a number of DNA vaccines are currently in clinical trials, none have been approved for use in humans. One of the challenges facing the use of DNA vaccines is that the responses generated in humans may be insufficient to prevent infection. To address this issue, scientists have investigated numerous methods to enhance the immunogenicity of DNA vaccines including the use of novel adjuvants and cytokines. For many diseases, including influenza, the generation of neutralizing antibodies produced by B lymphocytes is sufficient to protect against infection. The CD4 T cell response is essential for generating high levels of neutralizing antibodies in addition to eliciting memory T and B cell responses that provide protection against future infections. CD4 T cells recognize MHC class II epitopes presented on the surface of antigen presenting cells. Dr. Douglas Powell and Dr. John Zinckgraf at Antigen Express have demonstrated that immunization of mice with MHC class II epitopes derived from the H5N1 influenza hemagglutinin protein coupled to the proprietary Ii-Key peptide greatly enhances the CD4 T cell responses to a DNA vaccine encoding the H5N1 influenza hemagglutinin protein and may be used as a strategy to increase the immunogenicity of DNA vaccines.

    One of the major challenges facing immunization with many of the currently available vaccines is the need for refrigeration, often referred to as maintenance of the cold chain. This is a particularly difficult problem in developing countries with limited medical resources. One of the advantages of a vaccine utilizing peptides and DNA is that both of these components can be lyophilized, stored at ambient temperatures and reconstituted "on-site" with saline. "We have promising data in an animal model suggesting that we will be able to achieve levels of immunity consistent with protection from H5N1," said Dr. Powell. The company has recently completed a pre-IND meeting with the FDA and hopes to enter human clinical trials of its peptide vaccine against H5N1 later this year.

    About Generex

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

    For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

    Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

  13. Henk Snaph 15 maart 2006 12:55

    • Henk Snaph

      Lid sinds: 11 okt 2000

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 952

      Gegeven: 634

    •    Aantal posts: 10.940

    quote:

    DieGroeneGigant schreef:

    www.thestreet.com/_yahoo/stocks/broke...

    Gigant, mijn engels is niet goed genoeg dit verhaal in de juiste kontekst te plaatsen. Heb jij een korte verklaring a.u.b.

    Henks

    Gigant, heb een vertaalprogramma gevonden. Ben benieuwd wat dit bericht verder brengt want het zijn natuurlijk wel de jongen die nu nog met Generex bezig zijn.

    Henks
  14. [verwijderd] 15 maart 2006 13:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    In het kort: ze krijgen forse boete in verband met manipulatie mn short gaan met aandelen waaronder gnbt.

    "....illegal short-selling scheme involving 23 separate PIPE deals from 2000 to 2002...."

    Zouden ze het nu afleren ? Ik denk het niet.
  15. [verwijderd] 15 maart 2006 14:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    DJ Generex Biotechnology Announces Additional Preliminary Results In A Trial Of Generex Oral-lyn(TM) In Adolescent / Young Adult Patients With Type-1 Diabetes>GNBT

    03/15/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)


  16. [verwijderd] 15 maart 2006 20:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het is bij lange na niet meer zo druk op dit forum.
    Als je een paar maanden geleden kijk en nu is er een grote terug
    gang.
    Gelukkig is de koers alleen maar omhoog gegaan.
    $2,53 en ik ben een tevreden man.
    Heb dan weer een mooie rit achter me,klaar voor de volgende.

    Ben benieuwd wat die meeting in Londen teweeg gaat brengen.

    Groet, Ronald.
  19. [verwijderd] 15 maart 2006 21:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ronald76 schreef:

    Ik zit er gemiddeld in op $1,91 , niets te klagen dus.
    Waarom durf jij er niet boven de 2 in te stappen?

    groet,Ronald.?

    stijgin eerder puur op asian flue speculatie..

    en oralyn verhaal al stijgin vanaf 0,8 naar 2$
    dus vind dat er voorlopig al redelijk in beprijsd
  20. [verwijderd] 15 maart 2006 21:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=ronald76]
    Ik zit er gemiddeld in op $1,91 , niets te klagen dus.
    Waarom durf jij er niet boven de 2 in te stappen?

    groet,Ronald.?

    [/quote]
    stijgin eerder puur op asian flue speculatie..

    en oralyn verhaal al stijgin vanaf 0,8 naar 2$
    dus vind dat er voorlopig al redelijk in beprijsd
    Wat jezegt klopt er is echter een maar, in Amerika stijgt een aandeel des te harder als er wat te fantaseren valt.
    Ik zal je vertellen dat ik een verkoop order heb geplaatst op 2,53 en niet getreurd zal zijn als die niet word uitgevoerd.
    Ik denk dat dit aandeel voor het eine van het jaar op $5,zal staan.
    Heb in het verleden veel dag handel gedaan met dit aandeel en er goed geld mee verdiend.
    Ben huiverig geworden om er uit te stappen.
    Groet, Ronald.
2.656 Posts
Pagina: «« 1 ... 92 93 94 95 96 ... 133 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.217
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.875
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.848
Aedifica 3 926
Aegon 3.258 323.086
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.305
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 425
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.959
AMG 971 134.450
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.999
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.324
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.958
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449